Quick Answer
Kiniksa Pharmaceuticals International, plc reported Research And Development Expense of $96.85 million for the year ending 2025.
- Kiniksa Pharmaceuticals International, plc showed a decrease of -13.2% in Research And Development Expense from 2024 to 2025.
- This data is from Kiniksa Pharmaceuticals International, plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $9.27 million | Q3 2017: $14.01 million | Q1 2018: $12.63 million | Q2 2018: $17.20 million | Q3 2018: $20.64 million | Q1 2019: $59.25 million | Q2 2019: $30.85 million | Q3 2019: $22.01 million | Q1 2020: $20.90 million | Q2 2020: $22.32 million | Q3 2020: $31.42 million | Q1 2021: $28.68 million | Q2 2021: $23.95 million | Q3 2021: $19.24 million | Q1 2022: $20.82 million | Q2 2022: $13.80 million | Q3 2022: $16.49 million | Q1 2023: $15.17 million | Q2 2023: $23.77 million | Q3 2023: $17.11 million | Q1 2024: $26.33 million | Q2 2024: $24.02 million | Q3 2024: $26.06 million | Q1 2025: $19.33 million | Q2 2025: $18.75 million | Q3 2025: $24.17 million.
- Over the full 9 years of available data (2017 to 2025), Kiniksa Pharmaceuticals International, plc's Research And Development Expense has grown by 71.9%.
- Historical annual values: Fiscal year 2025: $96.85 million | Fiscal year 2024: $111.62 million | Fiscal year 2023: $76.10 million | Fiscal year 2022: $65.49 million | Fiscal year 2021: $99.30 million | Fiscal year 2020: $112.04 million | Fiscal year 2019: $135.00 million | Fiscal year 2018: $86.60 million | Fiscal year 2017: $56.36 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: